Supplementary Materials

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Characterizing the metabolic phenotype of cross-drug tolerant cancer cells in multiple tumor models.
  • Fig. S2. Testing the effect of glucose metabolism inhibition on cross-drug tolerance in multiple cell lines.
  • Fig. S3. Characterizing phenotypic and metabolic heterogeneity in drug-tolerant cells.
  • Fig. S4. Characterizing the role of ROS and the PPP in drug tolerance.
  • Fig. S5. HIF1α signaling, glucose uptake, and PPP in adaptive cross-drug tolerance.
  • Fig. S6. Testing the effect of G6PD inhibition on cross-drug tolerance with an inhibitor library.
  • Fig. S7. Computational modeling.
  • Fig. S8. Colocalization of Glut1 and CD44 in residual tumor mass.
  • Fig. S9. A PI3K inhibitor in a three-drug schedule with taxanes and anthracyclines improves outcomes.
  • Fig. S10. Proposed mechanism of drug-induced phenotypic and metabolic state transitions that drive cross-drug tolerance.
  • Table S1. Patient demographics for Fig. 6 (I to N).
  • Table S2. Patient demographics for Fig. 6O.
  • References (7376)

[Download PDF]